Ad hoc announcement pursuant to Art. 53 LR Full Year 2025 revenue of €104.2 million, in line with guidance, with 85% recurring revenues Recurring revenues of €88.1 million, +15% year-over-year, ...
Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results